Editorials

A novel combination therapy approach for the treatment of acute myeloid leukemia: the multi-kinase inhibitor sorafenib and the HDM2 inhibitor nutlin-3

Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
Vol. 97 No. 11 (2012): November, 2012 https://doi.org/10.3324/haematol.2012.078451